| Q35401301 | 3D pattern of brain atrophy in HIV/AIDS visualized using tensor-based morphometry |
| Q42743771 | 4-Aminopyridine improves spatial memory in a murine model of HIV-1 encephalitis |
| Q49961078 | 7T Brain MRS in HIV Infection: Correlation with Cognitive Impairment and Performance on Neuropsychological Tests. |
| Q34482480 | A machine learning approach for identifying amino acid signatures in the HIV env gene predictive of dementia |
| Q36119442 | A perspective on the proposal for neurocognitive disorder criteria in DSM-5 as applied to HIV-associated neurocognitive disorders. |
| Q43467476 | A survey on pulmonary pathogens and their antibiotic susceptibility among cystic fibrosis patients. |
| Q43489247 | Adaptation of the attention network in human immunodeficiency virus brain injury |
| Q36302078 | Adjunctive therapies for HIV-1 associated neurologic disease. |
| Q46966972 | Altered P-glycoprotein expression in AIDS patients with HIV encephalitis |
| Q37156385 | Amount of HIV DNA in peripheral blood mononuclear cells is proportional to the severity of HIV-1-associated neurocognitive disorders |
| Q33917623 | An exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIV+ adults |
| Q34267520 | Atypical progressive multifocal leukoencephalopathy in HIV with a high CD4 count: the use of magnetic resonance imaging plus spectrometry studies |
| Q45412296 | Brain CD8+ and cytotoxic T lymphocytes are associated with, and may be specific for, human immunodeficiency virus type 1 encephalitis in patients with acquired immunodeficiency syndrome |
| Q37516983 | Brain biopsy in AIDS patients: diagnostic yield and treatment applications |
| Q33614467 | Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals |
| Q45403949 | Ceftriaxone protects against the neurotoxicity of human immunodeficiency virus proteins |
| Q36839225 | Clinical utility of magnetic resonance spectroscopy to enhance diagnosis of HIV-associated mild neurocognitive disorder |
| Q33843510 | Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells |
| Q51942900 | Correlation between SIV Tat evolution and AIDS progression in cerebrospinal fluid of morphine-dependent and control macaques infected with SIV and SHIV. |
| Q30478136 | Correlation of acute humoral response with brain virus burden and survival time in pig-tailed macaques infected with the neurovirulent simian immunodeficiency virus SIVsmmFGb |
| Q36406259 | Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz |
| Q36672574 | Detection of anti-tat antibodies in CSF of individuals with HIV-associated neurocognitive disorders |
| Q37354387 | Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction |
| Q59357365 | Dimethyl Fumarate Prevents HIV-Induced Lysosomal Dysfunction and Cathepsin B Release from Macrophages |
| Q34784731 | Do common mental disorders decline over time in TB/HIV co-infected and HIV patients without TB who are on antiretroviral treatment? |
| Q37176655 | Effects of antiretroviral therapy on cognitive impairment |
| Q24631692 | Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy |
| Q30936809 | Evidence for predilection of macrophage infiltration patterns in the deeper midline and mesial temporal structures of the brain uniquely in patients with HIV-associated dementia |
| Q33311631 | Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era. |
| Q43378566 | Feline Immunodeficiency Virus Neuropathogenesis: A Model for HIV-Induced CNS Inflammation and Neurodegeneration |
| Q37015529 | Feline immunodeficiency virus neuropathogenesis: from cats to calcium |
| Q37335823 | GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration. |
| Q33936233 | Gene expression changes consistent with neuroAIDS and impaired working memory in HIV-1 transgenic rats. |
| Q33605737 | Gene expression patterns associated with neurological disease in human HIV infection |
| Q33716348 | Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. |
| Q37015469 | HIV Preclinical-Clinical Therapeutics Research: central nervous system approaches |
| Q55344050 | HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz. |
| Q31031123 | HIV and the central nervous system |
| Q43800797 | HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis |
| Q35276630 | HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease? |
| Q45296006 | HIV encephalitis simulating Huntington's disease |
| Q36552753 | HIV pharmacology: barriers to the eradication of HIV from the CNS. |
| Q40048514 | HIV-1 TAT inhibits microglial phagocytosis of Abeta peptide. |
| Q41763649 | HIV-1 Tat and morphine have interactive effects on oligodendrocyte survival and morphology |
| Q36633249 | HIV-1 encephalopathy among perinatally infected children: Neuropathogenesis and response to highly active antiretroviral therapy |
| Q33671675 | HIV-1-based defective lentiviral vectors efficiently transduce human monocytes-derived macrophages and suppress replication of wild-type HIV-1 |
| Q38441425 | HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. |
| Q34406750 | Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort |
| Q36302056 | Human brain derived cell culture models of HIV-1 infection |
| Q36203752 | Human immunodeficiency virus type 1 genetic diversity in the nervous system: evolutionary epiphenomenon or disease determinant? |
| Q35123435 | Human immunodeficiency virus type 1 infection of human brain-derived progenitor cells |
| Q36088274 | Impact of highly active antiretroviral therapy on organ-specific manifestations of HIV-1 infection. |
| Q34033558 | Impact of short-term combined antiretroviral therapy on brain virus burden in simian immunodeficiency virus-infected and CD8+ lymphocyte-depleted rhesus macaques |
| Q50553161 | Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. |
| Q33911855 | Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia |
| Q90667808 | Increases in compulsivity, inflammation, and neural injury in HIV transgenic rats with escalated methamphetamine self-administration under extended-access conditions |
| Q43586132 | Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia |
| Q33788874 | Interaction with CD4 and antibodies to CD4-induced epitopes of the envelope gp120 from a microglial cell-adapted human immunodeficiency virus type 1 isolate |
| Q34086976 | Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons |
| Q41557309 | Interhemispheric Asymmetries and Theta Activity in the Rostral Anterior Cingulate Cortex as EEG Signature of HIV-Related Depression: Gender Matters |
| Q45673013 | Levels of human immunodeficiency virus type 1 (HIV-1) replication in macrophages determines the severity of murine HIV-1 encephalitis. |
| Q40113932 | Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. |
| Q47218999 | Low-level HIV replication in mixed glial cultures is associated with alterations in the processing of p55(Gag). |
| Q39521282 | Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. |
| Q34312179 | Memantine for AIDS dementia complex: open-label report of ACTG 301. |
| Q82029821 | Neuroimaging of the HIV/AIDS patient |
| Q35221044 | Neurologic disease in captive lions (Panthera leo) with low-titer lion lentivirus infection |
| Q58855603 | Neurological disease in HIV-infected patients in the era of highly active antiretroviral treatment: a Brazilian experience |
| Q35810431 | Neuropathology of AIDS: An Autopsy Review of 284 Cases from Brazil Comparing the Findings Pre- and Post-HAART (Highly Active Antiretroviral Therapy) and Pre- and Postmortem Correlation. |
| Q34565848 | Neuropsychiatric complications of antiretroviral therapy |
| Q34313868 | Neuropsychiatric impact of hepatitis C on advanced HIV |
| Q33868874 | Neuropsychiatric manifestations of HIV infection and AIDS |
| Q31111043 | Neuropsychological and neuroimaging outcome of HIV-associated progressive multifocal leukoencephalopathy in the era of antiretroviral therapy |
| Q36856162 | Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS |
| Q28246161 | No health without mental health |
| Q41862645 | Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)--2',3'-dideoxycytidine (ddC): relevance to HIV-dementia |
| Q35078313 | Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment |
| Q34402559 | Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. |
| Q39724313 | Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort |
| Q37794385 | Rebuilding synaptic architecture in HIV-1 associated neurocognitive disease: a therapeutic strategy based on modulation of mixed lineage kinase |
| Q36142331 | Regional cortical thinning associated with detectable levels of HIV DNA. |
| Q45415194 | Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients |
| Q46396028 | Relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among nondemented individuals infected with HIV. |
| Q35125996 | Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications |
| Q37371300 | Second assessment of NeuroAIDS in Africa |
| Q45409291 | Sequence variation in the CC-chemokine ligand 2 promoter of pigtailed macaques is not associated with the incidence or severity of neuropathology in a simian immunodeficiency virus model of human immunodeficiency virus central nervous system disease |
| Q34995472 | Site-specific hyperphosphorylation of pRb in HIV-induced neurotoxicity |
| Q45434391 | The central nervous system is a viral reservoir in simian immunodeficiency virus--infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy |
| Q39220724 | The effect of highly active antiretroviral therapy on outcome of central nervous system herpesviruses infection in Cuban human immunodeficiency virus-infected individuals |
| Q45729626 | The indirect effects of virus infections |
| Q26750549 | The inhibition of microRNAs by HIV-1 Tat suppresses beta catenin activity in astrocytes |
| Q28300983 | The neuropathogenesis of AIDS |
| Q82029832 | The neuropathology of HIV |
| Q35945958 | The pattern and predictors of mortality of HIV/AIDS patients with neurologic manifestation in Ethiopia: a retrospective study |
| Q30411844 | The role of host genetics in the susceptibility for HIV-associated neurocognitive disorders |
| Q36302049 | The shifting patterns of HIV encephalitis neuropathology |
| Q34098327 | Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline |
| Q36799270 | Tripartite containing motif 32 modulates proliferation of human neural precursor cells in HIV-1 neurodegeneration |
| Q48110376 | Utility of brain biopsy in patients with acquired immunodeficiency syndrome before and after introduction of highly active antiretroviral therapy |
| Q80028671 | [Correlation between clinical apparatus-based differential diagnosis and neuropathological diagnosis in patients with AIDS] |